Telomir Pharmaceuticals (NASDAQ: TELO) has announced the peer-reviewed publication of preclinical data demonstrating that Telomir-Zn, its lead small-molecule therapeutic, suppresses tumor growth in prostate and triple-negative breast cancer (TNBC) models through selective modulation of intracellular iron and copper. The findings, published in the Journal of Oncology Research and Therapy, provide the scientific foundation for advancing Telomir-Zn toward a planned Phase 1/2 clinical trial in TNBC under the company's active Investigational New Drug (IND) application.
The study revealed that Telomir-Zn inhibits histone demethylases by depleting intracellular iron, selectively killing iron-dependent TNBC cells while sparing normal cells at concentrations more than 50-fold higher. Additionally, Telomir-Zn reactivated tumor-suppressor genes in a prostate cancer model, indicating a potential epigenetic mechanism of action. In TNBC xenograft models, Telomir-Zn reduced primary tumor size across several cell lines and significantly reduced metastatic dissemination in HCC1806 xenografts. Notably, in BT-549 xenografts, combining Telomir-Zn with paclitaxel produced significantly greater tumor reduction than either treatment alone, while MDA-MB-231 xenografts did not respond, indicating tumor-specific differences in sensitivity.
These results underscore the potential of Telomir-Zn as a targeted therapy for cancers that depend on metal homeostasis for survival. The company plans to initiate a Phase 1/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer, a disease with limited treatment options and poor prognosis. The IND clearance from the U.S. Food and Drug Administration allows the company to proceed with this trial.
Telomir Pharmaceuticals is a clinical-stage biotechnology company focused on developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer. The company's lead program, Telomir-Zn, is designed to modulate intracellular metal homeostasis and epigenetic regulation, offering a novel approach to cancer treatment.
The full press release is available at https://ibn.fm/mv3hn. For the latest news and updates on Telomir Pharmaceuticals, visit the company's newsroom at https://ibn.fm/TELO.
